The clustered regularly interspaced short palindromic repeats (CRISPR/Cas9) system is a recently discovered tool for genome editing that has quickly revolutionized the ability to generate site-specific mutations in a wide range of animal models, including nonhuman primates. Indeed, a significant number of scientific reports describing single or multiplex guide RNA microinjection, double-nicking strategies, site-specific knock-in and conditional knock-out have been published in less than three years. However, despite the great potential of this new technology, there are some limitations because of the presence of off-target genomic sites, which must be taken into consideration. To address this issue, various research teams have tried to improve the efficiency of the system through enzymatic modifications of the Cas9 protein or by the introduction of alternative strategies. Although several review articles are available that singly describe the molecular mechanism(s), applications and challenges of each of these strategies, a concise compilation of approaches is lacking. In the current review, we describe and evaluate most CRISPR/Cas9 approaches available at present, describing both mechanism of action, in addition to advantages or disadvantages. The primary goal of this work is to serve as a guide for not skilled researchers, facilitating the selection of the best strategy to target their gene of interest and allowing optimization of particular applications to the specific aims of the study. The present article also offers a unique perspective, focusing on the fact that CRISPR technology is opening a new genomic era, providing the means to manipulate specific genes in a targeted manner in all animal models, an endeavor previously considered to be difficult.
Introduction
Clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 is a new system of genome engineering that has transformed our ability to manipulate genes in many different animal models [1] . This technology uses the properties of an ancient adaptive immune system present in archaea and eubacteria [2] , used as a defense mechanism to protect the host cell against the presence of exogenous nucleic acids, such as viral DNA [3] [4] [5] . Even if different types of CRISPR are present in nature, one of the best characterized is the type II from Streptococcus pyogenes, which acts via the introduction of doublestrand breaks (DSBs) in the target genomic DNA [5] . At present, the workings of this system can be reproduced in vitro through the synthesis of a guide RNA (gRNA) plus the messenger RNA (mRNA) encoding the Cas9 protein, which are all co-transfected in cells [6, 7] or co-injected in the one-cell-stage embryos [8] [9] [10] [11] [12] [13] .
Owing to the simplicity of the CRISPR/Cas9 system, it is becoming widely used and accessible also to nonexperts in molecular biology; however, despite the significant potential and ease of use, some limitations of the approach need to be considered during its utilization, in particular the presence of offtarget effects [14] . For this reason, several research teams over the past 3 years have been working to improve the efficiency and specificity of this system. This still-evolving tool continues to provide a fast, customized and straightforward avenue for genome editing, a revolution that has already impacted nearly all areas of biology [15] , including clinical medicine [16] [17] [18] [19] . Although a rich literature concerning single aspects of gRNA injection, double-nicking strategy, conditional knock-out and site-specific knock-in is presently available, the aim of this article is indeed to provide the reader with a general review of all the various applications of the CRISPR/Cas9 technology, guiding nonexpert researchers to facilitate selection of the optimal strategy for their studies. This review highlights the extraordinary opportunity offered by CRISPR/Cas9, enabling the exploration of function through genome editing in all experimental animal models.
Knock-out by gRNA injection
The first examples of CRISPR/Cas9 exploitation were based on the interaction between the Cas9 protein and a single small gRNA, which is a chimera made by the fusion between a 20-nucleotide crRNA sequence (CRISPR RNA) homologous to the target genomic region, as well as a tracrRNA (trans-activating CRISPR RNA) backbone that folds into a hairpin structure necessary for the interaction with the Cas9 [20] . This interaction between Cas9 and the gRNA then causes a DNA DSB in the specific genomic region complementary to the crRNA portion of the gRNA (Figure 1 ). The cleavage is produced three nucleotides upstream of a protospacer adjacent motif (PAM) 5 0 -NGG/NCC-3 0 , which is required for cleavage to occur [21, 22] . Once the DSB is produced, endogenous DNA repair mechanisms are activated to mend the damage, including nonhomologous end joining (NHEJ) or homology-directed repair (HDR), using either a random insertion/deletion process (InDels) or precise editing, respectively [23] . The first applications of the CRISPR/Cas9 system in cells primarily took advantage of the NHEJ system. In the absence of a template, this error-prone repair mechanism introduces or deletes random nucleotides at the site of cleavage, leading to the generation of genetic mutations in an unpredictable manner. However, selecting the beginning of the coding sequence (CDS) of a gene as the target region will likely result in a knock-out of the encoded protein, because of the introduction of a frameshift in the sequence or the generation of a premature stop codon. From 2013 onward, the possibility of in vivo applications of the CRISPR/Cas9 system in zebrafish [10] , mouse [11] and human cell lines [6] emerged. In addition, given the tremendous versatility of the system, the number of publications using other organisms continues to rapidly increase ( Figure 2 ). Along with this increase in utilization is the expanding need for highthroughput screening strategies to facilitate mutant phenotype selection, leading to the emergence of several new, rapid and cheaper genotyping methods [24] [25] [26] [27] .
Injection of multiple gRNAs
One of the greatest advantages offered by the NHEJ system is that it can work simultaneously in different loci of the genome, thanks to the high specificity of gRNAs; therefore, up to five different gRNAs have been co-injected with the Cas9 mRNA in the same embryo or cell line, resulting in a multiple loss-of-function phenotype. Encouraging results have been obtained in both mice [11, 28] and zebrafish [29] , where a combination of multiple knock-out phenotypes was observed in the same individual with a high rate of heritability [10] .
However, as for any genome-editing methodology, such as transcription activator-like effector nucleases (TALEN) or zincfinger nucleases (ZFN), to avoid side effects related to toxicity or unintended off-target effects, particular attention must be paid to ensure the correct concentration of gRNAs is injected. Despite the great success of this innovative technique, its increasing potential has been brought into question by different research teams that independently demonstrated unwanted effects on many off-target sites, presumably because of tolerability of mismatches between the target sequence and the gRNA [14, 30, 31] . In fact, off-target mutations are sometimes observed at a frequency rate higher than the intended event, representing a major limitation of this technique, in particular for therapeutic and clinical applications. As a consequence, to provide a solid genotype-phenotype correlation, it is necessary to detect the possible presence of off-target mutations through different methods, such as the T7 endonuclease I assay [32] , the Surveyor assay [32] , the ChIP-seq [33] or the last reported GUIDE-seq [34] . Several online tools are also available to assist in designing gRNAs to target-specific regions in the genome (http://crispr. mit.edu/; http://chopchop.rc.fas.harvard.edu/; www.multicrispr. net; http://www.broadinstitute.org/rnai/public/analysis-tools/ sgrna-design; www.rgenome.net), although it must be taken into consideration that these are in silico predictions, and, therefore, the cellular impact must be carefully scrutinized [35] [36] [37] .
Alternative strategies for minimizing off-target effects
To improve the specificity of the CRISPR/Cas9, the scientific community has started to consider and design alternative strategies to circumvent the limitations of the CRISPR/Cas9 system. For example, a strategy was developed that combines a mutant version of the Cas9 protein (Cas9n-D10A) with two gRNAs complementary to the opposite strands of the target region [38] . In this novel Cas9, one amino acid substitution (D10A) leads to the inactivation of the nuclease catalytic activity, converting the protein from a nuclease into a nickase enzyme that makes a single-stranded breaks (SSBs) instead of a DSB at the specific target site. Once the SSB is introduced in the genomic region, it is predominantly repaired by the high-fidelity base excision repair pathway, an essential repair system naturally present in cells that corrects DNA alterations frequently occurring in the genome [39] . It has been demonstrated that the Cas9n-D10A, directed by a pair of appropriately spaced and oriented gRNAs (injected at a 1:1 ratio), is able to simultaneously introduce SSBs on both strands of the target region, minimizing the Cas9 activity in other loci of the genome. This is because of the fact that simultaneous binding of two different gRNAs to nearby offtarget sites is unlikely [38] .
Another similar strategy is based on the use of the dimeric RNA-guided FokI nuclease (RFNs), which can recognize extended sequences and modify DNA sequences with high efficiencies in a manner similar to that of Cas9n-D10A. The RFN cleavage activity depends mostly on the binding of two different gRNAs to the target region with specific spacing and orientation [40] . In this case, the RFN is fused with the FokI nuclease domain at the N-terminus of the Cas9 protein, following the same principles of ZFNs and TALENs. Moreover, a high-fidelity S. pyogenes Cas9 nuclease variant (SpCas9-HF1), with strong on-target efficiency and reduced off-target effects, has been generated by Kleinstiver and collaborators [41] . The authors speculate that the interaction between the Cas9 protein and the gRNA has more energy than necessary for the recognition of a target site; thus, reducing this 'excess of energy' can increase both specificity of the complex while decreasing off-target activity [41] . More recently, a new genome-editing tool, the CRISPR/Cpf1 from Prevotella and Francisella bacteria, has been described as a precise and robust system compared with the traditional CRISPR/Cas9 system [42] . Cpf1 is a single RNA-guided endonuclease that lacks the tracrRNA and introduces DSBs with a 4 or 5 nucleotide 5 0 overhang upstream of a short T-rich PAM, instead of the G-rich PAM recognized by the Cas9 systems. These features simplify the design of shorter gRNAs as well as their synthesis.
Novel applications
The plethora of recent discoveries not only expands the CRISPR toolkits for functional studies but also broadens our knowledge about the variety of natural CRISPR/Cas9 systems. Recently, a new class of gRNAs, called scaffold-small conditional RNAs, has been engineered to recruit activator or repressor proteins in a precise region of the genome, thus avoiding protein fusion [43] . Furthermore, the advent of the nuclease-dead dCas9, generated through the introduction of point mutations to block its endonuclease activity, it has been introduced a new type of transcription regulation of the genome [44] . By fusing the dCas9 to transcriptional effector proteins, it is possible to perform gene interference (CRISPRi) or activation (CRISPRa) [45] . Moreover, dCas9 protein fused to epigenetic-modifying enzymes can be used to insert locus-specific modifications such as acetylation or methylation [46] .
Site-specific knock-in
As mentioned before, DSBs in a genome can be also mended by another repair system called HDR. This is a more precise but less efficient mechanism that can be exploited when an accurate integration of an exogenous DNA fragment in a genomic locus is desirable, for example to put a reporter gene under the control of an endogenous promoter. Although DSBs induced by the Cas9 protein are preferentially repaired by the NHEJ system, this is not ideal for knocking-in genes, which requires greater precision. The first applications of knock-in by CRISPR/Cas9 deal with just short fragments of DNA, such as restriction enzyme sites that are integrated with a low efficiency rate. Recent improvements in the system now permit the insertion of longer exogenous DNA sequences [47] . In this last case, a DNA template (also called a donor vector) carrying two homology arms flanking the genomic target sequence is co-injected with the gRNA and Cas9 mRNA. The correct integration events can be easily assessed by genomic polymerase chain reaction using primers specific for the target locus and the donor vector. To monitor efficiency of the system, transgenic eGFP or other reporter genes can also be used to easily detect the mutated genotype [48, 49] , although a wide screening of correct integration events is still required [50] . However, the necessity to generate a specific donor vector carrying homology arms for each target region strongly increases the complexity and cost of the work. A donor plasmid can still be integrated into the genome after linearization by nucleases even in absence of homology arms to the target sequence. In this case, integration efficiency is high but frequently imprecise, as it involves the NHEJ system. Nevertheless, excellent results have been obtained in zebrafish, including knock-in approaches to insert eGFP and the transcriptional activator Gal4 into the zebrafish genome in a simple and flexible way with high efficiency [51] . A disadvantage of this strategy is the potential to disrupt the CDS of targeted endogenous genes and/or modify their expression pattern, as insertion events can also occur in cis-regulatory elements [52] . To bypass these technical limitations, Li and colleagues developed an intron targeting-mediated knock-in approach, in which the CDS and regulatory elements of the targeted endogenous genes are not affected by insertion [53] .
Conditional knock-out
To assess where and when a gene is active, the CRISPR/Cas9 system has recently been used to rapidly edit gene function in a tissue-dependent or in a time-dependent manner through what is generally called conditional knock-out. This strategy is particularly useful in cellular and developmental biology studies or, specifically, for the analysis of essential genes with early lethality whose null mutation does not allow the animal to reach later stages of development. In the past, the generation of conditional knock-outs was typically performed via homologous recombination through complex and time-consuming steps (e.g. embryonic stem cells (ES) cell route in mouse). With the versatility and wide availability of the CRISPR/Cas9 system, it is now possible to generate conditional alleles in mouse, rat, zebrafish, sea squirt, fruit fly and nematodes and in a relatively easy and rapid manner [9, [54] [55] [56] [57] [58] . Similar to the knock-in strategy, an exogenous DNA template can be used to generate a conditional knock-out. For example, a donor plasmid containing a floxed exon (flanking/flanked by loxP) flanked by short homology arms can be injected in embryos with one or two gRNAs, leading to the introduction of loxP sites at specified genomic locations through HDR. Moreover, to simplify the process and reduce the use of laboratory animals [59] , it is also possible to induce in vitro conditional knock-out using mouse embryonic stem cells [60] .
Noncoding RNA editing CRISPR/Cas9 has been shown to be a powerful tool for the editing of protein-coding genes in different animal models. Interestingly, it has also recently been demonstrated that it can be applied also to the knock-out or knock-in of noncoding RNAs, such as microRNAs (miRNAs) and long-noncoding RNAs, which are key players in the regulation of gene expression. In this type of approach, the greatest challenge derives from the lack of an open reading frame and, as a consequence, from the necessity of larger mutation to introduce loss of function of a noncoding genes. Moreover, InDel mutations introduced by CRISPR/Cas9 system are not suitable for every purpose, especially if it is desired to destroy an untranslated gene that physically overlaps with other protein-coding genes. To bypass these limitations, two targeting gRNAs and a deletion of fragments as large as possible are recommended. However, without prior information about the position of these noncoding elements, a genome-wide screening is required. Cheng et al. recently described the Molecular Chipper technology, an easy approach to generate dense single gRNA libraries based on random fragmentation and a type III restriction enzyme digestion of input DNA, allowing the identification of novel cis-regulatory domains in noncoding regions. Using this approach, the authors were able to identify the pre-miR-142 region and two previously unrecognized cis-domains, which are important for the miRNA biogenesis [61] . A similar approach has also been extended to the screening of coding genes using semi-random primers containing a PAM complementary sequence, which is particularly useful for species that are poorly characterized genetically [62] .
Regarding miRNAs, an alternative strategy is to design a gRNA targeting the 5 0 end of the noncoding transcript, given that this region contains the seed sequence that is both crucial for mRNA recognition and also undergoes specific cleavage by Drosha, a double-stranded RNA-specific endoribonuclease involved in miRNA processing. In this manner, an accurate gene knock-out is possible, and the biogenesis of the miRNA is also blocked [63] . In the future, a new alternative strategy to consider could be to use specifically designed PAM-presenting oligonucleotides, which stimulate endonucleolytic cleavage directly on single-stranded RNA, without affecting the corresponding genomic region [64] .
Conclusions
There are no doubts that the CRISPR/Cas9 system has revolutionized the field of genome editing in cell lines, as well as in many different animal models extending beyond mice. The great innovation introduced by this new tool derives not only from the fact that it enhances our ability to study and understand gene functions but also because it has the potential to transform clinical medicine in the near future [65] . Moreover, the versatility of CRISPR technology to both activate and repress gene function in either coding or noncoding regions of the genome further amplifies its future utility and applicability in diverse areas, such as human therapeutics, microbial engineering and agricultural biotechnology. At the moment, it remains possibly the most exciting and simplest technology of genome engineering currently discovered, with the potential of being exploitable even by nonexperts in molecular biology. However, it must be noted that in the context of the potential therapeutic applications, and in particular the possibility of therapeutic intervention for genetic disorders or cancer, this methodology is still in an immature phase of development.
In view of clinical applications, several scientists are trying to improve the specificity of the system to cleave the DNA at specific locations to reduce off-target effects, which remains the major limitation of the CRISPR/Cas9 technology as mentioned above. A recent publication describes editing of nonviable human embryos using the CRISPR/Cas9 system [66] , which is now the first time that human embryos have been edited. Although this work undoubtedly opens arguable ethical issues that will require further discussions and considerations, the results demonstrated that the technique is not yet ready for therapeutic applications in humans given the low editing efficiency (<15%).
Regardless, this is most likely just the beginning of a revolutionary technology that will be regularly used by next-generation scientists and, considering its rapid advance, we might envision CRISPR technology becoming a widespread tool in human gene therapy [67] .
Key Points
• CRISPR/Cas9 is a new system of genome editing that has revolutionized the ability to generate site-specific mutations in many different animal models.
• Thanks to its versatility and simplicity, the CRISPR/ Cas9 has the potential of being exploitable even by nonexperts in molecular biology.
• At the moment, many publications describe independ ently the molecular mechanism, the applications and the limits of the CRISPR/Cas9 technology, but a succinct compilation of all of them is needed.
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